Philip Angell-Manning

Philip Angell-Manning serves as the Head of Chemistry Manufacturing & Controls (CMC) at Scancell, a clinical stage company focused on developing active immune-oncology therapies, since July 2025. Prior to this, Philip held the position of Director of CMC at Akamis Bio from August 2017 to June 2025, overseeing tumor gene therapies and international manufacturing activities. Philip also worked at the University of Oxford as a Process Development Manager at the Jenner Institute’s Clinical BioManufacturing Facility from 2014 to 2017, contributing to vaccine development. Previous experience includes roles as Production Manager at Glysure Ltd and Oxford BioMedica, where Philip played significant roles in facility startup and gene therapy production, and as a Technician at Bio Products Laboratory Limited focused on GMP production of human plasma proteins. Philip holds an MSc in Neuroscience from The University of Manchester and a BSc in Biological Sciences from The University of Salford.